Immunovaccine Inc. (TSX-V: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates. The DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology. This patented delivery platform is a breakthrough in vaccine development because it creates a “depot effect” that distinguishes it in the competitive vaccine sector.
With a goal of developing premium vaccines for cancer and infectious diseases, the company has two promising DepoVax-based products in clinical trials – DPX-0907 and DPX-Survivac. Immunovaccine continues to strengthen its pipeline through licensing and strategic partnering. With demonstrated safety-in-man and recent partnerships with Merck KGaA, Pfizer, Oncothyreon, IRX Therapeutics, Oncotherapy Science, NCI, NRC, and Defense Research & Development Canada, the value of the DepoVax platform is significantly enhanced.